Merck, known as MSD outside the United States and Canada, announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 3-7. Presentations will feature new or updated findings from Merck's broad portfolio of cancer medicines: KEYTRUDA; WELIREG™ (belzutifan); LYNPARZA® (olaparib, in collaboration with AstraZeneca); and LENVIMA® (lenvatinib, in collaboration with Eisai). Additionally, Merck will present data from its diverse pipeline of immuno-therapeutic candidates, including the investigational anti-LAG-3 therapy favezelimab and the investigational anti-ILT3 therapy MK-0482. Key data from Merck's portfolio to be presented at ASCO: First presentation of distant metastasis-free survival (DMFS) and updated recurrence-free survival findings from the Phase 3 KEYNOTE-716 trial evaluating KEYTRUDA as adjuvant therapy in resected stage IIB and IIC melanoma (Abstract #LBA9500).

Earlier this year, Merck reported that KEYNOTE-716 met its key secondary endpoint of DMFS as adjuvant treatment for these patients. Additionally, health-related quality-of-life data for KEYNOTE-716 will be presented for the first time (Abstract #9581); Data from a subgroup analysis of the Phase 3 KEYNOTE-091 trial evaluating outcomes related to surgery, disease burden and adjuvant chemotherapy in patients with stage IB (greater than 4 cm) – stage III non-small cell lung cancer (NSCLC) treated with KEYTRUDA in the adjuvant setting following complete resection (Abstract #8512); Additional long-term efficacy analyses of the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA in the adjuvant setting for patients with renal cell carcinoma (RCC) who are at intermediate-high to high risk of recurrence following nephrectomy (Abstract #4512); Exploratory analysis of the Phase 3 KEYNOTE-426 trial evaluating KEYTRUDA plus axitinib as first-line therapy for advanced clear cell RCC following progression after first subsequent therapy (Abstract #4513); Exploratory analysis from the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA plus chemotherapy in the neoadjuvant setting in patients with early-stage triple-negative breast cancer investigating event-free survival by residual cancer burden (Abstract #502); Subgroup analysis from the Phase 3 KEYNOTE-826 trial evaluating KEYTRUDA plus chemotherapy as first-line treatment for patients with persistent, recurrent or metastatic cervical cancer (Abstract #5506); Three-year follow-up data from the Phase 1 LITESPARK-001 trial evaluating WELIREG from the advanced clear cell RCC cohort (Abstract #4509) and two-year follow-up data from the Phase 2 LITESPARK-004 trial evaluating WELIREG in von-Hippel-Lindau disease (Abstract #4546). Key data from Merck's pipeline to be presented at ASCO: First presentation of results from Cohort 1 of a Phase 1/2 study evaluating the anti-LAG-3 antibody, favezelimab plus KEYTRUDA in patients with anti-PD-1-naïve relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) (Abstract #7516).

Results for Cohort 2 of this study evaluating favezelimab plus KEYTRUDA in patients with R/R cHL after anti-PD-1 treatment will also be presented for the first time (Abstract #7545).